About cervical cancer
Cervical cancer is the abnormal growth of cancerous cells in the tissues of the cervix. It is the world's fourth most common cause of death in women. The disease can be classified as squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma originates in the lining of the cervix, while adenocarcinoma arises in cervical cells. Cervical cancer is caused due to the infection of HPV. There are no signs and symptoms to identify the early stages of cervical cancer, but it can be identified through regular check-ups. Vaginal bleeding and pelvic pain are usually observed as signs and symptoms of cervical cancer. Before cancer detected in the cervix, cervix cells go through changes, called as dysplasia, in which abnormal cells start to expose in the cervical tissue. Over a period, the abnormal cells may developed into cancer cells and begin to grow and spread more deeply into the cervix and surrounding areas.
Technavio's analysts forecast the global cervical cancer market to grow at a CAGR of 4.87% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the global cervical cancer market for the period of 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment and prevention of cervical cancer.
Technavio's report, Global Cervical Cancer Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cervical cancer market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
F. Hoffmann-La RocheGlaxoSmithKlineMerck
Other prominent vendors
Advaxis ImmunotherapiesBionor PharmaDendreon CorporationInovio PharmaceuticalsISA PharmaceuticalsOtsuka PharmaceuticalsProfectus BiosciencesVirometixZeria Pharmaceuticals
Key market driver
Increase in incidence rateFor a full, detailed list, view our report
Key market challenge
Adverse effects of drugs and vaccinesFor a full, detailed list, view our report
Key market trend
Patient assistance programsFor a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2019 and what will the growth rate be?What are the key market trends?What is driving this market?What are the challenges to market growth?Who are the key vendors in this market space?What are the market opportunities and threats faced by the key vendors?What are the strengths and weaknesses of the key vendors?
Technavio Announces the Publication of its Research Report – Global Cervical Cancer Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Cervical Cancer Market: F. Hoffmann-La Roche, GlaxoSmithKline and Merck
Other Prominent Vendors in the market are: Advaxis Immunotherapies, Bionor Pharma, Dendreon Corporation, Inovio Pharmaceuticals, ISA Pharmaceuticals, Otsuka Pharmaceuticals, Profectus Biosciences, Virometix and Zeria Pharmaceuticals
Commenting on the report, an analyst from Technavio’s team said: “There are several treatment options available for cervical cancer: surgery, radiotherapy, chemotherapy, and targeted therapy as well asprophylactic vaccines. However, these therapies are associated with adverse side effects, lengthy treatment periods, and suboptimal patient compliance. In addition, vaccines costs are high, and the global cost of unmet needs for medicines for cervical cancer is approximately $26 million. Available therapies are not enough to cure the disease permanently, but survival rates can be exceeded. Therefore, an opportunity exists for pharma companies to develop new drugs that will address the unmet needs of the market.”
According to the report, cancer drugs are expensive, and some individuals cannot afford chemotherapy. Reimbursement plans such as public reimbursement programs reduce the financial burden of treatment. The reimbursement status of drugs is dynamic in nature and varies across countries. Factors such as the lack of cost-effectiveness can impede the reimbursement coverage of drugs.
Further, the report states that the therapies are expensive, and radiation therapy can itself cause other types of cancer, increasing the cost of treatment. Thus the overall cost of cervical cancer treatment is high, leading to fewer individuals opting for them, especially in developing countries in APAC, such as India and China, and EMEA.
F. Hoffmann-La Roche, GlaxoSmithKline, Merck ,Advaxis Immunotherapies, Bionor Pharma, Dendreon Corporation, Inovio Pharmaceuticals, ISA Pharmaceuticals, Otsuka Pharmaceuticals, Profectus Biosciences, Virometix, Zeria Pharmaceuticals
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook